AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management
- AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.
- 04/19/2024
|
AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management
- MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE®+ cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure's legacy cryoSHPERE® device. The product is currently in an extended limited launch period in the United States, wit.
- 04/18/2024
|
AtriCure to Announce First Quarter 2024 Financial Results
- MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2024 financial results on Wednesday, May 1, 2024. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, May 1, 2024, to discuss its first quarter 2024 financial results. Those interested in listen.
- 04/10/2024
|
AtriCure, Inc. (ATRC) Q4 2023 Earnings Call Transcript
- AtriCure, Inc. (ATRC) Q4 2023 Earnings Call Transcript
- 02/15/2024
|
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings
- The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 02/15/2024
|
AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates
- AtriCure (ATRC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.09 per share a year ago.
- 02/15/2024
|
AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results
- MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2023 and full year 2023 financial results. “Our 2023 results showcase the broad-based expansion of our many growth drivers, balanced by disciplined investments as we make progress towards sustained profitability,” said Michael Carrel, Presiden.
- 02/15/2024
|
Seeking Clues to AtriCure (ATRC) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
- Get a deeper insight into the potential performance of AtriCure (ATRC) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
- 02/12/2024
|
AtriCure to Announce Fourth Quarter and Full Year 2023 Financial Results and Participate in 2024 BTIG Medical Technology Conference
- MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Thursday, February 15, 2024, to discuss its fourth quarter and full year 2023 finan.
- 01/25/2024
|
AtriCure Appoints Shlomi Nachman to the Board of Directors
- MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Directors. Mr. Nachman's long and distinguished career in the medical device industry has placed him at the forefront of new market development and growth, serving most recently as Company Group Chairman within Joh.
- 01/04/2024
|
AtriCure to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
- MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference. AtriCure's management is scheduled to present on Wednesday, January 10, 2024, at 7:30 a.m. Pacific Standard Time. Interested parties may access a live audio webcast by v.
- 12/20/2023
|
Wall Street Analysts Predict a 36.34% Upside in AtriCure (ATRC): Here's What You Should Know
- The consensus price target hints at a 36.3% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 11/15/2023
|
AtriCure to Participate in the Piper Sandler 35th Annual Healthcare Conference
- MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 35th Annual Healthcare Conference. AtriCure's management is scheduled to participate in a fireside chat on Wednesday, November 29, 2023, at 9:30 a.m. Eastern Standard Time. Interested parties may access.
- 11/15/2023
|
AtriCure Releases 2023 ESG Report
- MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the company has published its 2023 Environmental, Social and Governance (ESG) Report highlighting the company's corporate responsibility and sustainability initiatives. “At AtriCure, our focus on making a positive difference for patients is at the heart.
- 11/14/2023
|
AtriCure: Appeal Lures For This Cure
- AtriCure has seen solid revenue growth but needs more operating leverage to improve its bottom line. The company's shares have experienced a meaningful pullback from their highs in June. Despite continued losses, AtriCure's progress on the margin front and expected sales growth in 2024 make its sales multiple compelling.
- 11/10/2023
|
All You Need to Know About AtriCure (ATRC) Rating Upgrade to Buy
- AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 11/06/2023
|
AtriCure, Inc. (ATRC) Q3 2023 Earnings Call Transcript
- AtriCure, Inc. (NASDAQ:ATRC ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Marissa Bych – Gilmartin Group, Investor Relations Mike Carrel – President and Chief Executive Officer Angie Wirick – Chief Financial Officer Conference Call Participants Robbie Marcus – J.P. Morgan Danielle Antalffy – UBS Mike Matson – Needham and Company Sam Eiber – BTIG Suraj Kalia – Oppenheimer & Co Operator Good afternoon, and welcome to AtriCure's Third Quarter 2023 Earnings Conference Call.
- 11/01/2023
|
AtriCure (ATRC) Reports Q3 Earnings: What Key Metrics Have to Say
- Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 11/01/2023
|
AtriCure (ATRC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
- While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 07/25/2023
|
AtriCure, Inc. (ATRC) Q2 2023 Earnings Call Transcript
- AtriCure, Inc. (NASDAQ:ATRC ) Q2 2023 Earnings Conference Call July 25, 2023 4:30 PM ET Company Participants Marissa Bych - Vice President-Gilmartin Group Mike Carrel - President & CEO Angie Wirick - CFO Conference Call Participants Robert Marcus - J.P. Morgan William Plovanic - Canaccord Matthew O'Brien - Piper Sandler Marie Thibault - BTIG Frederick Wise - Stifel Michael Matson - Needham Suraj Kalia - Oppenheimer Operator Good afternoon, and welcome to AtriCure's Second Quarter 2023 Earnings Conference Call.
- 07/25/2023
|
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
- AtriCure (ATRC) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.32 per share a year ago.
- 07/25/2023
|
AtriCure to Participate at Upcoming Investor Conferences
- MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in two upcoming investor conferences. AtriCure will be participating in the Canaccord Genuity 43rd Annual Growth Conference. AtriCure's management is scheduled to present on Thursday, August 10, 2023, at 8:00 a.m. East.
- 07/21/2023
|
AtriCure to Announce Second Quarter 2023 Financial Results
- MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release second quarter 2023 financial results on Tuesday, July 25, 2023. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, July 25, 2023, to discuss its second quarter 2023 financial results. Those interested in listenin.
- 07/03/2023
|
AtriCure: Operating Leverage Is Required As A Cure
- AtriCure, Inc. has seen continued momentum in Afib and related markets. The company sees solid revenue growth, which, amidst a retreat in the share price, has resulted in rapidly narrowing sales multiples. While this combination is attractive, I am still waiting for (more) operating leverage to hit the bottom line.
- 06/14/2023
|
AtriCure, Inc. (ATRC) Q1 2023 Earnings Call Transcript
- AtriCure, Inc. (NASDAQ:ATRC ) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ET Company Participants Marissa Bych – Vice President-Gilmartin Group Mike Carrel – President and Chief Executive Officer Angie Wirick – Chief Financial Officer Conference Call Participants Matthew O'Brien – Piper Sandler Marie Thibault – BTIG John McAulay – Stifel Joseph Conway – Needham Suraj Kalia – Oppenheimer Operator Good afternoon, and welcome to AtriCure's First Quarter 2023 Earnings Conference Call. At this time, all participants are in listen-only mode.
- 05/02/2023
|
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
- AtriCure (ATRC) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.33 per share a year ago.
- 05/02/2023
|
AtriCure (ATRC) Moves 7.5% Higher: Will This Strength Last?
- AtriCure (ATRC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 03/27/2023
|
AtriCure, Inc. (ATRC) Q4 2022 Earnings Call Transcript
- AtriCure, Inc. (NASDAQ:ATRC ) Q4 2022 Earnings Conference Call February 21, 2023 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group, Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Robbie Marcus - J.P. Morgan Bill Plovanic - Canaccord Marie Thibault - BTIG Mike Matson - Needham Suraj Kalia - Oppenheimer Rick Wise - Stifel Operator Good afternoon, and welcome to AtriCure's Q4 2022 Earnings Conference Call.
- 02/21/2023
|
AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates
- AtriCure (ATRC) delivered earnings and revenue surprises of 50% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/21/2023
|
AtriCure: Despite Reasonable Top-Line Growth, No Change To Hold Thesis
- A reasonable period of top-line growth across the core portfolio last quarter, coupled with strong guidance for FY22. Despite this, operating losses continue to widen, and NOPAT is thin even when capitalizing on R&D.
- 12/29/2022
|
AtriCure to Present at 34th Annual Piper Sandler Healthcare Conference
- MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will present at the 34th Annual Piper Sandler Healthcare Conference.
- 11/08/2022
|
AtriCure, Inc. (ATRC) Q3 2022 Earnings Call Transcript
- AtriCure, Inc. (NASDAQ:ATRC ) Q3 2022 Earnings Conference Call November 1, 2022 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Robert Marcus - JPMorgan Rick Wise - Stifel Marie Thibault - BTIG John Young - Canaccord Genuity Matthew O'Brien - Piper Sandler Michael Matson - Needham & Company Suraj Kalia - Oppenheimer Operator Good afternoon, and welcome to AtriCure's Q3 2022 Earnings Conference Call. My name is Stacy, and I'll be your coordinator for the call today.
- 11/01/2022
|
AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates
- AtriCure (ATRC) delivered earnings and revenue surprises of -8% and 2.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/01/2022
|
AtriCure Announces Investor Education Webcast with Hybrid AF Therapy Key Opinion Leaders
- MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will host an investor education webcast at 2:00 p.m. Eastern Time on Wednesday, September 28, 2022, focusing on Hybrid AF Therapy. The webcast will include remarks from management and key opinion leaders, as well as an interactive question and answer ses
- 09/06/2022
|
AtriCure, Inc. (ATRC) CEO Mike Carrel on Q2 2022 Results - Earnings Call Transcript
- AtriCure, Inc. (NASDAQ:ATRC ) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Marissa Bych - Investor Relations Mike Carrel - President and Chief Executive Officer Angie Wirick - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan John McAulay - Stifel Marie Thibault - BTIG William Plovanic - Canaccord David Saxon - Needham Suraj Kalia - Oppenheimer Matthew O'Brien - PSC Operator Good afternoon and welcome to the AtriCure Second Quarter 2022 Earnings Conference Call. My name is Michelle and I will be your coordinator for today's call.
- 08/03/2022
|
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
- AtriCure (ATRC) delivered earnings and revenue surprises of -6.67% and 6.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/02/2022
|
AtriCure Inc. (ATRC) CEO Michael Carrel on Q1 2022 Results - Earnings Call Transcript
- AtriCure Inc. (NASDAQ:ATRC ) Q1 2022 Results Conference Call May 3, 2022 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group Michael Carrel - President, CEO Angela Wirick - CFO Conference Call Participants Robbie Marcus - JPMorgan Danielle Antalffy - SVB Leerink John McAulay - Stifel Sam Eiber - BTIG David Saxon - Needham Matthew O'Brien - Piper Sandler Suraj Kalia - Oppenheimer Operator Good afternoon, and welcome to AtriCure's First Quarter 2022 Earnings Conference Call. My name is Jeff and I will be your coordinator for call today.
- 05/03/2022
|
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
- AtriCure (ATRC) delivered earnings and revenue surprises of -22.22% and 4.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/03/2022
|
Wall Street Analysts Think AtriCure (ATRC) Could Surge 52%: Read This Before Placing a Bet
- The average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in AtriCure (ATRC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 02/16/2022
|
AtriCure Inc. (ATRC) CEO Michael Carrel on Q4 2021 Results - Earnings Call Transcript
- AtriCure Inc. (ATRC) CEO Michael Carrel on Q4 2021 Results - Earnings Call Transcript
- 02/15/2022
|
AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates
- AtriCure (ATRC) delivered earnings and revenue surprises of -15.38% and 0.99%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/15/2022
|
AtriCure, Inc. (ATRC) CEO Mike Carrel on Q3 2021 Results - Earnings Call Transcript
- AtriCure, Inc. (ATRC) CEO Mike Carrel on Q3 2021 Results - Earnings Call Transcript
- 11/03/2021
|
AtriCure's (ATRC) CEO Mike Carrel on Q2 2021 Results - Earnings Call Transcript
- AtriCure's (ATRC) CEO Mike Carrel on Q2 2021 Results - Earnings Call Transcript
- 08/07/2021
|
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
- AtriCure (ATRC) delivered earnings and revenue surprises of -9.09% and 15.91%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2021
|
AtriCure to Participate at the Canaccord 41st Annual Growth Conference
- MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Canaccord 41st Annual Growth Conference. AtriCure's management is scheduled to present on Wednesday, August 11, 2021, at 8:00 a.m. Eastern Time. Interested parties may access a live and archived audio webcast of the presentation by visiting the “Inv
- 07/30/2021
|
These are Wall Street's top analysts favorite stocks heading into June
- TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Deere & Advanced Micro Devices.
- 05/30/2021
|
AtriCure (ATRC) Soars 8.8%: Is Further Upside Left in the Stock?
- AtriCure (ATRC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 04/30/2021
|
AtriCure, Inc.'s (ATRC) CEO Mike Carrel on Q1 2021 Results - Earnings Call Transcript
- AtriCure, Inc.'s (ATRC) CEO Mike Carrel on Q1 2021 Results - Earnings Call Transcript
- 04/27/2021
|
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
- AtriCure (ATRC) delivered earnings and revenue surprises of 7.32% and 5.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 04/27/2021
|
AtriCure: Q1 Earnings Insights
- Shares of AtriCure (NASDAQ:ATRC) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 11.11% year over year to ($0.32), which beat the estimate of ($0.37).
- 04/27/2021
|
Preview: AtriCure's Earnings
- AtriCure (NASDAQ:ATRC) announces its next round of earnings this Tuesday, April 27. Here is Benzinga's everything-that-matters guide for this Tuesday's Q1 earnings announcement.
- 04/26/2021
|
AtriCure, Inc. (ATRC) CEO Mike Carrel on Q4 2020 Results - Earnings Call Transcript
- AtriCure, Inc. (ATRC) CEO Mike Carrel on Q4 2020 Results - Earnings Call Transcript
- 02/23/2021
|
AtriCure to Announce Fourth Quarter and Full Year 2020 Financial Results
- MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2020 financial results on Tuesday, February 23, 2021. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, February 23, 2021 to discuss its fourth quarter and full year 2020 financial results. The call may be accessed through an operator
- 02/02/2021
|
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2020
- MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial results for the fourth quarter and full year 2020. “We are pleased with our fourth quarter and full-year results which reflect the resiliency and strength of our team, as well as the overarching unmet need in our core markets. COVID-19 continues to impact our revenue as procedure volumes remain b
- 01/11/2021
|
AtriCure (ATRC) Looks Good: Stock Adds 5.1% in Session
- AtriCure (ATRC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- 12/21/2020
|
AtriCure to Participate in the 39th Annual J.P. Morgan Healthcare Conference
- MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming 39th Annual J.P. Morgan Healthcare Conference being held virtually. AtriCure's management is scheduled to present on Monday, January 11, 2021, at 10:00 a.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by visi
- 12/14/2020
|
AtriCure, Inc. (ATRC) CEO Mike Carrel on Q3 2020 Results - Earnings Call Transcript
- AtriCure, Inc. (ATRC) CEO Mike Carrel on Q3 2020 Results - Earnings Call Transcript
- 11/08/2020
|
AtriCure to Participate in Upcoming Investor Conferences
- MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in two upcoming investor conferences. AtriCure's management team will be presenting at the Stifel Healthcare Conference in a virtual setting on Wednesday, November 18, 2020, at 11:20 a.m. Eastern Time. Interested parties may access a live and archived webcast of th
- 10/26/2020
|
AtriCure to Announce Third Quarter 2020 Financial Results
- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today anno
- 10/13/2020
|
AQR Capital Management LLC Invests $705,000 in AtriCure Inc. (NASDAQ:ATRC)
- AQR Capital Management LLC acquired a new position in AtriCure Inc. (NASDAQ:ATRC) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 15,683 shares of the medical device company’s stock, valued at approximately $705,000. Several other institutional investors also recently made […]
- 10/02/2020
|
AtriCure (NASDAQ:ATRC) Shares Gap Down to $40.02
- Shares of AtriCure Inc. (NASDAQ:ATRC) gapped down before the market opened on Wednesday . The stock had previously closed at $40.02, but opened at $36.41. AtriCure shares last traded at $36.11, with a volume of 5,503 shares changing hands. ATRC has been the subject of a number of research reports. BTIG Research reiterated a “buy” […]
- 10/02/2020
|
AtriCure, Inc.: Surgical Device Maker's Growth Engines Face Fatal Complications (NASDAQ:ATRC)
- AtriCure's Convergent procedure, on which its hopes for growth are pinned, is unlikely to gain traction given a poor safety profile and lack of incremental efficacy relative to catheter-based procedures.
- 09/30/2020
|
Stifel Financial Corp Reduces Position in AtriCure Inc. (NASDAQ:ATRC)
- Stifel Financial Corp cut its position in AtriCure Inc. (NASDAQ:ATRC) by 34.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,384 shares of the medical device company’s stock after selling 8,239 shares during the period. Stifel Financial Corp’s holdings in […]
- 09/27/2020
|
Captrust Financial Advisors Takes Position in AtriCure Inc. (NASDAQ:ATRC)
- Captrust Financial Advisors acquired a new stake in AtriCure Inc. (NASDAQ:ATRC) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 4,500 shares of the medical device company’s stock, valued at approximately $204,000. Several other hedge funds and other institutional investors also recently made changes […]
- 09/21/2020
|
First Republic Investment Management Inc. Purchases Shares of 5,181 AtriCure Inc. (NASDAQ:ATRC)
- First Republic Investment Management Inc. acquired a new position in shares of AtriCure Inc. (NASDAQ:ATRC) during the second quarter, Holdings Channel reports. The fund acquired 5,181 shares of the medical device company’s stock, valued at approximately $233,000. Several other hedge funds also recently added to or reduced their stakes in the company. Ameritas Investment Partners […]
- 09/19/2020
|
AtriCure Inc. (NASDAQ:ATRC) Expected to Post Quarterly Sales of $48.16 Million
- Equities analysts expect AtriCure Inc. (NASDAQ:ATRC) to announce $48.16 million in sales for the current quarter, Zacks reports. Five analysts have made estimates for AtriCure’s earnings, with the highest sales estimate coming in at $53.32 million and the lowest estimate coming in at $40.80 million. AtriCure reported sales of $56.61 million during the same quarter […]
- 09/19/2020
|
AtriCure: Steady Growth, Lackluster Margins (NASDAQ:ATRC)
- AtriCure has been a steady revenue growth play in medtech. Troublesome is that the business has been losing money since the IPO fifteen years ago, although the burn rate is manageable and is ''financed'' with dilution.
- 09/18/2020
|
Critical Review: AtriCure (NASDAQ:ATRC) & Repare Therapeutics (NASDAQ:PYPD)
- Repare Therapeutics (NASDAQ:PYPD) and AtriCure (NASDAQ:ATRC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations. Insider & Institutional Ownership 5.2% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 93.5% […]
- 09/16/2020
|
Trexquant Investment LP Invests $892,000 in AtriCure Inc. (NASDAQ:ATRC)
- Trexquant Investment LP acquired a new position in shares of AtriCure Inc. (NASDAQ:ATRC) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 19,843 shares of the medical device company’s stock, valued at approximately $892,000. Several other hedge funds have also bought […]
- 08/23/2020
|
Stocks To Watch: Walmart, Target, Kandi And Gold vs. Bitcoin
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 08/15/2020
|
AtriCure Announces Angie Wirick as Chief Financial Officer
- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the position of Chief Financial Officer (CFO) for personal reasons and moving into an advisory role through March 5, 2021. Angie Wirick, current Vice President of Finance, has been promoted to CFO effective immediately.
- 08/06/2020
|
AtriCure Announces Angie Wirick as Chief Financial Officer
- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced
- 08/06/2020
|
Envestnet Asset Management Inc. Buys Shares of 10,085 AtriCure Inc. (NASDAQ:ATRC)
- Envestnet Asset Management Inc. purchased a new stake in AtriCure Inc. (NASDAQ:ATRC) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 10,085 shares of the medical device company’s stock, valued at approximately $453,000. Several other hedge funds and other institutional investors have also added […]
- 08/05/2020
|
Analysts Anticipate AtriCure Inc. (NASDAQ:ATRC) Will Announce Quarterly Sales of $48.16 Million
- Wall Street brokerages forecast that AtriCure Inc. (NASDAQ:ATRC) will report sales of $49.76 million for the current quarter, according to Zacks. Five analysts have provided estimates for AtriCure’s earnings, with estimates ranging from $45.80 million to $53.32 million. AtriCure reported sales of $56.61 million during the same quarter last year, which indicates a negative year-over-year […]
- 08/05/2020
|
AtriCure Inc. (ATRC): Were Hedge Funds Right About Buying This Stock?
- We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
- 08/03/2020
|
Piper Sandler Equities Analysts Increase Earnings Estimates for AtriCure Inc. (NASDAQ:ATRC)
- AtriCure Inc. (NASDAQ:ATRC) – Investment analysts at Piper Sandler upped their FY2020 earnings per share estimates for AtriCure in a research report issued on Tuesday, July 28th. Piper Sandler analyst M. O’brien now expects that the medical device company will post earnings of ($1.36) per share for the year, up from their previous estimate of […]
- 08/02/2020
|
AtriCure Inc. (NASDAQ:ATRC) Forecasted to Earn Q3 2020 Earnings of ($0.29) Per Share
- AtriCure Inc. (NASDAQ:ATRC) – Equities research analysts at SVB Leerink issued their Q3 2020 EPS estimates for shares of AtriCure in a research report issued to clients and investors on Wednesday, July 29th. SVB Leerink analyst D. Antalffy forecasts that the medical device company will post earnings per share of ($0.29) for the quarter. SVB […]
- 08/02/2020
|
U.S. IPO Week Ahead: Rocket Companies Shoots For The Moon In A 6-IPO Week
- Six IPOs and one SPAC are scheduled to raise $4.6 billion in the week ahead, with Rocket Mortgage parent Rocket Companies slated to complete the year's largest US IPO to date.
- 08/01/2020
|
Analysts Have Made A Financial Statement On AtriCure, Inc.'s (NASDAQ:ATRC) Second-Quarter Report
- AtriCure, Inc. (NASDAQ:ATRC) defied analyst predictions to release its second-quarter results, which were ahead of...
- 07/30/2020
|
AtriCure to Participate at Upcoming Investor Conferences
- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in several upcoming investor conferences.
- 07/29/2020
|
AtriCure Inc (ATRC) Q2 2020 Earnings Call Transcript
- Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control, including risks and uncertainties described from time-to-time in AtriCure's SEC filings. AtriCure's results may differ materially from those projected.
- 07/29/2020
|
The Daily Biotech Pulse: Merck's Breakthrough Therapy Designation, Sonoma Surges On Sanitizer News, Sanofi-Glaxo And More
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 28)
Axonics Modulation Technologies Inc (NASDAQ: AXNX)
Capricor Therapeutics Inc (NASDAQ: CAPR)
Fulgent Genetics Inc...
- 07/29/2020
|
AtriCure, Inc. (ATRC) CEO Mike Carrel on Q2 2020 Results - Earnings Call Transcript
- AtriCure, Inc. (NASDAQ:ATRC) Q2 2020 Earnings Conference Call July 28, 2020 4:30 P.M.
- 07/28/2020
|
Recap: AtriCure Q2 Earnings
- Shares of AtriCure (NASDAQ:ATRC) were flat in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share fell 123.53% over the past year to ($0.38), which beat the estimate of ($0.61).Revenue of $40,824,000 decreased by 30.70% from the same period last year, which beat the estimate of $35,450,000.Looking Ahead AtriCure hasn't issued any earnings guidance for the time being.AtriCure hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: Jul 28, 2020View more earnings on ATRCTime: 04:30 PMET Webcast URL: https://edge.media-server.com/mmc/p/5q5jzg3qTechnicals 52-week high: $51.76Company's 52-week low was at $22.57Price action over last quarter: Up 3.59%Company Overview AtriCure Inc an atrial fibrillation solutions company that provides products, professional education, and support for clinical science to reduce the economic and social burden of atrial fibrillation. Its products line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offer a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.See more from Benzinga * Earnings Scheduled For July 28, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/28/2020
|
AtriCure Reports Second Quarter 2020 Financial Results
- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2020 financial results.
- 07/28/2020
|
The Daily Biotech Pulse: Spectrum's Positive Dementia Readout, Pfizer, BioNTech Start Late-Stage Coronavirus Trial, resTORbio Receives COVID-19 Funding
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 27)
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT)
Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO)...
- 07/28/2020
|
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
- Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Although there were promising updates from...
- 07/26/2020
|
Acutus Medical Files For IPO For Commercialization Push
- Acutus Medical has filed to raise $75 million in a U.S. IPO, although the final figure may differ.
- 07/23/2020
|
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
- AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/21/2020
|
$34.56 Million in Sales Expected for AtriCure Inc. (NASDAQ:ATRC) This Quarter
- Wall Street analysts forecast that AtriCure Inc. (NASDAQ:ATRC) will announce sales of $34.56 million for the current quarter, according to Zacks. Five analysts have provided estimates for AtriCure’s earnings, with estimates ranging from $25.80 million to $42.70 million. AtriCure posted sales of $58.91 million in the same quarter last year, which would indicate a negative […]
- 07/13/2020
|
AtriCure to Announce Second Quarter 2020 Financial Results
- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2020 financial results on Tuesday, July 28, 2020.
- 07/07/2020
|
Xenon Lights Market Trajectory & Analytics to 2027 - COVID-19 Updated - ResearchAndMarkets.com
|
Global Atrial Fibrillation Surgery Market 2020-2025 - Ambulatory Surgical Center Segment is Forecast to be the Fastest-Growing Segment - ResearchAndMarkets.com
|
Is Apple about to buy smart speaker giant Sonos?
- A Sonos-Apple allegiance could be on the cards
- 06/23/2020
|
Hedge Funds Are Buying AtriCure Inc. (ATRC)
- We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
- 06/19/2020
|
Global Outlook for the Cryosurgery Devices Market to 2025 - Rising Preference for Minimally Invasive Surgeries Driving Market Growth - ResearchAndMarkets.com
|
The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 18)
ADC Therapeutics SA (NYSE:...
- 05/19/2020
|
Edited Transcript of ATRC earnings conference call or presentation 29-Apr-20 8:30pm GMT
- Q1 2020 AtriCure Inc Earnings Call
- 05/18/2020
|
Stocks That Hit 52-Week Highs On Monday
|
The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger
|
Stocks That Hit 52-Week Highs On Wednesday
|
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 12)
Acceleron Pharma Inc (NASDAQ...
- 05/13/2020
|
Protalix Fabry Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
- Protalix reported positive data from its Fabry disease trial. AtriCure reported positive data from its CONVERGE Study. Oyster Point Pharma reported mixed toplin
- 05/12/2020
|
Stocks That Hit 52-Week Highs On Tuesday
|
Edited Transcript of ATRC earnings conference call or presentation 29-Apr-20 8:30pm GMT
- Q1 2020 AtriCure Inc Earnings Call
- 05/12/2020
|
AtriCure Announces Pricing of Public Offering of Common Stock
- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the pricing of its underwritten offering of 3,977,273 shares of its common stock at a price to the public of $44.00 per share pursuant to its existing automatic shelf registration statement. Gross proceeds to AtriCure from the offering are expected to be approximately $175 million, before deducting underwriting discounts and commissions and estimated offering expenses. AtriCure has granted to the underwriters of the offering a 30-day option to purchase up to an additional 596,590 shares of common stock on the same terms and conditions. The offering is expected to close on May 14, 2020, subject to customary closing conditions. AtriCure intends to use the net proceeds from the offering for working capital and other general corporate purposes, which may include repayment of debt or long-term liabilities, and other potential corporate or market development activities.
- 05/12/2020
|
AtriCure Announces Pricing of Public Offering of Common Stock
- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today anno
- 05/12/2020
|
U.S. RESEARCH ROUNDUP-Acushnet Holdings, Equity Residential, Fiserv
- Wall Street securities analysts revised their ratings and price targets
on several U.S.-listed companies, including Acushnet Holdings, Equity Residential and Fiserv, on
Monday.
HIGHLIGHTS
* Acushnet Holdings Corp : Stephens raises target price to $27 from $24
* Equity Residential : Evercore ISI raises to in-line from underperform
* Fiserv Inc : Keybanc raises target price to $115 from $108
* GTT Communications Inc : SunTrust Robinson cuts to hold from buy
* UDR Inc : Evercore ISI raises to in-line from underperform
Following is a summary of research actions on U.S. companies reported by Reuters on Monday.
Stock entries are in alphabetical order.
* Abbvie Inc : SVB Leerink raises price target to $122 from $107
* Accelerate Diagnostics Inc : Piper Sandler cuts target price to $14 from $16
* Acushnet Holdings Corp : Compass Point raises TP to $22.25 from $21.50
* Acushnet Holdings Corp : Keybanc raises target price to $31 from $28
* Acushnet Holdings Corp : Stephens raises target price to $27 from $24
* Advance Auto Parts Inc : UBS raises target price to $140 from $135
* AIG : UBS cuts target price to $45 from $49
* Air Lease Corp : Deutsche Bank cuts target price to $36 from $45
* Air Lease Corp : Stephens raises target price to $36 from $30
* Airgain Inc : Northland Capital Markets raises target price to $23
* Alarm.Com Holdings Inc : Credit Suisse cuts target price to $62 from $64
* Albemarle Corp : RBC raises target price to $66 from $64
* Albemarle Corp : SunTrust Robinson cuts target price to $65 from $90
* Allegiant Travel Co : Evercore ISI cuts target price to $95 from $100
* Allscripts Healthcare Solutions : Canaccord Genuity cuts TP to $11 from $13
* Amdocs Ltd : Citigroup cuts price target to $76 from $83
* Amedisys Inc : Raymond James cuts price target to $210 from $225
* Amedisys Inc : UBS cuts target price to $190 from $208
* American Axle & Manufacturing Holdings : Citigroup raises TP to $7.5 from $6
* American Axle & Manufacturing Holdings : RBC raises target price to $7 from $5
* American Homes 4 Rent : Evercore ISI raises target price to $27 from $25
* Ameriprise Financial Inc : RBC raises target price to $155 from $145
* Amerisourcebergen Corp : Deutsche Bank raises target price to $98 from $93
* Amphastar Pharmaceuticals Inc : BMO raises price target to $21 from $20
* Angi Homeservices Inc : Citigroup raises price target to $10 from $6.5
* Aon Plc : Citigroup cuts price target to $230 from $240
* Aon Plc : KBW raises target price to $192 from $184
* Aon Plc : UBS cuts target price to $197 from $202
* Apache Corp : CFRA cuts to sell from hold; raises price target to $9
* Apache Corp : MKM Partners cuts target price by $1 to $19
* Aptiv Plc : Benchmark cuts price target to $87 from $90
* Arch Capital Group Ltd : UBS cuts target price to $39 from $43
* Atara Biotherapeutics Inc : Jefferies cuts target price to $11 from $13
* Athene Holding Ltd : BMO cuts price target to $60 from $63
* Atricure Inc : BTIG raises target price to $56 from $45
* Atricure Inc : Needham raises target price to $63 from $49
* Atricure Inc : Oppenheimer raises price target to $52 from $45
* Atricure Inc : SVB Leerink raises price target to $55 from $50
* Autonation Inc : CFRA cuts price target by $10 to $50
* Avalonbay Communities Inc : Evercore ISI cuts target price to $181 from $189
* Avista Corp : Guggenheim cuts target price to $38 from $39
* Bain Capital Specialty Finance : Citigroup raises price target to $10 from $7.5
* Ball Corp : Citigroup cuts price target to $86 from $89
* Ball Corp : Northland Capital Markets cuts target price to $80
* Baudax Bio Inc : Oppenheimer cuts price target to $14 from $16
* Bellring Brands Inc : Stifel cuts target price to $23 from $25
* BJ's Restaurants Inc : Deutsche Bank raises target price to $27 from $26
* Bloomin' Brands Inc : BMO raises price target to $10 from $9
* Bloomin' Brands Inc : Deutsche Bank raises target price to $15 from $14
* Bloomin' Brands Inc : Guggenheim raises target price to $15 from $11
* Bloomin' Brands Inc : Raymond James cuts target price to $14 from $15
* BP Midstream Partners LP : Mizuho raises target price to $14 from $13
* Broadridge Financial Solutions : Piper Sandler cuts TP to $120 from $124
* Broadridge Financial Solutions : Rosenblatt Securities ups TP to $115 from $101
* Brookfield Infrastructure Partners LP : BMO raises price target to $46 from $45
* Brookfield Infrastructure Partners LP : Scotiabank cuts Tp to $50 from $51
* Brookfield Property Partners LP : Canaccord Genuity cuts TP to $12 from $13
* Brookfield Property Partners LP : CIBC cuts target price to $18 from $20.50
* Brookfield Property Partners LP : RBC cuts target price to $18 from $22
* Bruker Corp : BTIG cuts price target to $50 from $57
* Cabot Oil & Gas Corp : Tudor Pickering Holt cuts to hold from buy
* Calithera Biosciences Inc : Citigroup raises price target to $10 from $7
* Callaway Golf Co : >: Compass Point cuts target price to $17.50 from $20
* Callaway Golf Co : Compass Point cuts target price to $17.50 from $20
* Camden Property Trust : Evercore ISI cuts target price to $98 from $102
* Camden Property Trust : Stifel raises target price to $96 from $91
* Cardtronics Plc : D.A. Davidson cuts target price to $34 from $40
* Cardtronics Plc : SunTrust Robinson raises target price to $29 from $23
* Cargurus Inc : RBC raises target price to $25 from $22
* Carnival : HSBC raises to buy from hold; cuts target price to $15.9 from $45.3
* Carrier Global Corp : Citigroup raises price target to $20 from $17
* Carvana Co : Oppenheimer raises price target to $127 from $95
* Carvana Co : Oppenheimer raises target price to $127 from $95
* Casella Waste Systems Inc : Jefferies raises target price to $56 from $52
* Casella Waste Systems Inc : Raymond James raises target price to $56 from $49
* Casella Waste Systems Inc : Stifel raises target price to $47 from $45
* Cellectis : Citigroup cuts price target to $15 from $16
* Centurylink Inc : SunTrust Robinson cuts target price to $9 from $10
* Ceridian Hcm Holding Inc : Jefferies raises target price to $65 from $60
* Chevron Corp : Independent Research raises target price to $98 from $90; hold
* CNX Resources Corp : Tudor Pickering Holt cuts to hold from buy
* Cognizant Technology Solutions : Evercore ISI cuts target price to $53 from $55
* Cognizant Technology Solutions Corp : HSBC cuts target price to $56 from $70
* Coherus Biosciences Inc : Citigroup cuts price target to $30 from $31
* Conagra Brands Inc : SunTrust Robinson cuts to hold from buy
* Consolidated Edison Inc : Evercore ISI cuts target price to $85 from $86
* Continental Resources : TD Securities raises target price to $14.50 from $13.50
* Cooper Tire & Rubber Co : JP Morgan cuts target price to $29 from $30
* Corporate Office Properties Trust : SunTrust Robinson raises TP to $28 from $26
* Corteva Inc : RBC raises target price to $31 from $27
* Covanta Holding : Stifel raises to hold from sell; raises TP to $9.50 from $6.50
* Crocs Inc : Piper Sandler raises target price to $28 from $24
* Cross Country Healthcare Inc : BMO cuts price target to $8 from $11
* Cryoport Inc : Stephens raises target price to $23 from $21
* CVR Energy Inc : Credit Suisse raises target price to $19 from $16
* Cytomx Therapeutics Inc : Wedbush raises target price to $16 from $11
* Danaher Corp : Evercore ISI raises target price to $175 from $150
* Danaher Corp : RBC raises target price to $173 from $159
* Datadog Inc : RBC raises target price to $50 from $43
* Dentsply Sirona : Barrington Research cuts to market perform from outperform
* Dentsply Sirona Inc : UBS cuts target price to $44 from $59
* Dicerna Pharmaceuticals : SunTrust Robinson raises target price to $33 from $28
* Diebold Nixdorf Inc : JP Morgan raises target price to $7 from $6
* Diebold Nixdorf Inc : JP Morgan raises to neutral from underweight
* Discovery Inc : Rosenblatt Securities cuts price target to $24 from $27
* Dish Network Corp : RBC cuts target price to $32 from $39
* Domtar : D.A. Davidson cuts to neutral from buy; cuts TP to $26 from $44
* Domtar Corp : Scotiabank cuts target price to $29 from $30
* Domtar Corp : TD Securities raises target price to $26 from $22
* E. W. Scripps Co : Benchmark cuts target price to $15 from $24
* E. W. Scripps Co : Guggenheim raises target price to $8 from $6.50
* Edison Intl.
- 05/11/2020
|
AtriCure Announces $100M Common Stock Offering
|
ArtiCure Announcds $100M Common Stock Offering
|
AtriCure Announces Proposed Public Offering of Common Stock
- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced a proposed underwritten public offering in which it expects to issue and sell approximately $100 million of shares of its common stock pursuant to its existing automatic shelf registration statement. In connection with this offering, AtriCure plans to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of its common stock at the public offering price less the underwriting discounts and commissions. AtriCure intends to use the net proceeds from the offering for working capital and other general corporate purposes, which may include repayment of debt or long-term liabilities, and other potential corporate or market development activities.
- 05/11/2020
|
AtriCure Announces Proposed Public Offering of Common Stock
- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today anno
- 05/11/2020
|
The Top Stocks To Buy Now
- Individual stock picking is increasingly important. Continue to concentrate on healthcare and technology. Here are the top stocks to buy now.
- 05/09/2020
|
AtriCure Announces Results from CONVERGE IDE Clinical Trial
- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the results from the CONVERGE IDE clinical trial. This first-of-its-kind trial, designed to demonstrate superiority, showed an 18% difference in favor of the hybrid Convergent procedure as compared to endocardial catheter ablation alone. The results of the trial were presented as part of the late-breaking clinical trials at the Heart Rhythm Society’s (HRS) Annual Scientific Session and were broadcasted virtually via the Heart Rhythm 365 digital platform.
- 05/08/2020
|
Atrial Appendage Occluder Market Global Insights 2020, Forecast to 2026 | Boston Scientific Corporation, SentreHEART Inc., Occlutech
- May 08, 2020 Xherald --
Global Atrial Appendage Occluder Market, delivering a must-read report for industry stakeholders wanting to understand the strategic...
- 05/08/2020
|
AtriCure Announces Results from CONVERGE IDE Clinical Trial
- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today anno
- 05/08/2020
|
Q1 2020 Earnings Forecast for AtriCure Inc. (NASDAQ:ATRC) Issued By SVB Leerink
- AtriCure Inc. (NASDAQ:ATRC) – SVB Leerink increased their Q1 2020 earnings estimates for shares of AtriCure in a report released on Tuesday, April 28th. SVB Leerink analyst D. Antalffy now anticipates that the medical device company will post earnings of ($0.26) per share for the quarter, up from their previous estimate of ($0.32). SVB Leerink […]
- 05/02/2020
|
Edited Transcript of VRAY earnings conference call or presentation 30-Apr-20 8:30pm GMT
- Q1 2020 ViewRay Inc Earnings Call
- 05/01/2020
|
AtriCure Inc (ATRC) Q1 2020 Earnings Call Transcript
- ATRC earnings call for the period ending March 31, 2020.
- 04/30/2020
|
AtriCure Announces Investor Update Webcast on May 8, 2020 in Conjunction with the 41st Annual Heart Rhythm Society (HRS) Virtual Meeting
- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will host an analyst and institutional investor update webcast at 1:00 p.m. Eastern Time on Friday, May 8, 2020, to coincide with
- 04/30/2020
|
Needham Believes Atricure (NASDAQ: ATRC) Won’t Stop Here
- Needham analyst Michael Matson reiterated a Buy rating on Atricure (ATRC – Research Report) today and set a price target
- 04/30/2020
|
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Blueprint Medicines (BPMC)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atricure (ATRC) and Blueprint Medicines (BPMC) with bullish
- 04/30/2020
|
Stock Traders Buy Large Volume of Call Options on AtriCure (NASDAQ:ATRC)
- AtriCure Inc. (NASDAQ:ATRC) was the recipient of unusually large options trading activity on Wednesday. Traders bought 2,279 call options on the stock. This represents an increase of approximately 830% compared to the typical volume of 245 call options. NASDAQ:ATRC opened at $41.39 on Thursday. The company has a debt-to-equity ratio of 0.30, a quick ratio […]
- 04/30/2020
|
AtriCure, Inc. (ATRC) CEO Michael Carrel on Q1 2020 Results - Earnings Call Transcript
- AtriCure, Inc. (NASDAQ:ATRC) Q1 2020 Earnings Conference Call April 29, 2020, 16:30 ET Company Participants Lynn Lewis - Gilmartin Group Michael Carrel - CEO, P
- 04/30/2020
|
Atricure (ATRC) Gets a Buy Rating from Oppenheimer
- Oppenheimer analyst Suraj Kalia maintained a Buy rating on Atricure (ATRC – Research Report) yesterday and set a price target
- 04/30/2020
|
BTIG Believes Atricure (NASDAQ: ATRC) Still Has Room to Grow
- In a report released yesterday,
Marie Thibault
from BTIG reiterated a
Buy
rating on Atricure (
ATRC
–
Research Report
), with a price target of
$45.00
. The company’s shares closed last Wednesday at $41.39, close to its 52-week high of $44.51.
Accord
- 04/30/2020
|
Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $45
|
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
- AtriCure (ATRC) delivered earnings and revenue surprises of 5.26% and 0.27%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 04/29/2020
|
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
- AtriCure (ATRC) delivered earnings and revenue surprises of 5.26% and 0.27%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 04/29/2020
|
AtriCure: 1Q Earnings Snapshot
- MASON, Ohio (AP) _ AtriCure Inc. (ATRC) on Wednesday reported a loss of $16.4 million in its first quarter.
On a per-share basis, the Mason, Ohio-based company said it had a loss of 42 cents. Losses, adjusted for non-recurring costs, were 36 cents pe
- 04/29/2020
|
AtriCure Reports First Quarter 2020 Financial Results
- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2020 financial results.
- 04/29/2020
|
The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 28.) * AstraZeneca plc (NYSE: AZN) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) * Black Diamond
- 04/29/2020
|
Axonics Names Michael H. Carrel as Chairman of its Board of Directors
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation ("SNM") devices for the treatment of urinary and bowel dysfunction, announced today the appointment of Michael H. Carrel as chairman
- 04/29/2020
|
AtriCure reports Q1 EPS (42c), consensus (41c) ATRC
- AtriCure reports Q1 EPS (42c), consensus (41c) ATRC
- 04/29/2020
|
The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs April 28.)
AstraZeneca plc (NYSE:...
- 04/29/2020
|
Untreated heart attacks negative for Abiomed, says Piper Sandler ABMD;BSX;MDT;ATRC
- Untreated heart attacks negative for Abiomed, says Piper Sandler Piper Sandler ABMD BSX MDT ATRC
- 04/28/2020
|
JP Morgan Maintains Overweight on AtriCure, Lowers Price Target to $39
|
AtriCure to Participate at Upcoming Investor Conferences
- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in two upcoming investor conferences.
- 04/27/2020
|
AtriCure (NASDAQ:ATRC) Rating Lowered to Hold at BidaskClub
- AtriCure (NASDAQ:ATRC) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a report released on Saturday, BidAskClub reports. Several other analysts also recently weighed in on the company. Needham & Company LLC raised their target price on AtriCure from $48.00 to $52.00 and gave the company a “buy” rating […]
- 04/27/2020
|
The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight
- The week ended April 24 turned out to be an up-and-down one for biotech stocks, as the sector swayed along with the broader market. Two FDA approvals came through this week,...
- 04/26/2020
|
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
- AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/22/2020
|
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
- AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/22/2020
|
AtriCure (ATRC) to Release Quarterly Earnings on Wednesday
- AtriCure (NASDAQ:ATRC) is scheduled to announce its earnings results after the market closes on Wednesday, April 29th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter. AtriCure has set its FY 2020 After-Hours guidance at -1.24–1.14 EPS and its FY20 guidance at -$1.24 to -$1.14 EPS.Persons that are interested in […]
- 04/22/2020
|
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
|
AtriCure Inc. (NASDAQ:ATRC) SVP Justin J. Noznesky Sells 10,000 Shares of Stock
- AtriCure Inc. (NASDAQ:ATRC) SVP Justin J. Noznesky sold 10,000 shares of the firm’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $40.00, for a total value of $400,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. ATRC […]
- 04/21/2020
|
AtriCure (NASDAQ:ATRC) Coverage Initiated by Analysts at Oppenheimer
- Research analysts at Oppenheimer initiated coverage on shares of AtriCure (NASDAQ:ATRC) in a research report issued to clients and investors on Sunday, Benzinga reports. The firm set an “outperform” rating and a $45.00 price target on the medical device company’s stock. Oppenheimer’s price objective indicates a potential upside of 11.30% from the stock’s current price. […]
- 04/21/2020
|
AtriCure Inc. (NASDAQ:ATRC) Shares Purchased by Ladenburg Thalmann Financial Services Inc.
- Ladenburg Thalmann Financial Services Inc. boosted its position in AtriCure Inc. (NASDAQ:ATRC) by 770.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,311 shares of the medical device company’s stock after purchasing an additional 4,701 shares during the period. Ladenburg Thalmann Financial Services […]
- 04/19/2020
|
Picking Winners And Losers: Best Stocks To Buy Now
- The market rally should become more selective going forward. Risk reward continues to favor buying down days. Here are the top stocks to buy now.
- 04/17/2020
|
ViewRay Announces Appointment of B. Kristine Johnson to its Board of Directors
- ViewRay, Inc. (Nasdaq: VRAY) announced the appointment of B. Kristine Johnson to its Board of Directors effective April 14, 2020.
- 04/16/2020
|
AtriCure to Announce First Quarter 2020 Financial Results
- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2020 financial results on Wednesday, April 29, 2020.
- 04/15/2020
|
Time To Worry? Analysts Just Downgraded Their AtriCure, Inc. (NASDAQ:ATRC) Outlook
- Market forces rained on the parade of AtriCure, Inc. (NASDAQ:ATRC) shareholders today, when the analysts downgraded...
- 04/14/2020
|
Some Analysts Just Cut Their AtriCure, Inc. (NASDAQ:ATRC) Estimates
- Market forces rained on the parade of AtriCure, Inc. (NASDAQ:ATRC) shareholders today, when the analysts downgraded...
- 04/14/2020
|
AtriCure Sees Unusually High Options Volume (NASDAQ:ATRC)
- AtriCure Inc. (NASDAQ:ATRC) was the target of some unusual options trading activity on Monday. Stock investors purchased 1,500 call options on the company. This represents an increase of approximately 1,479% compared to the average volume of 95 call options. A number of analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares […]
- 04/14/2020
|
Goldman Sachs Group Inc. Trims Position in AtriCure Inc. (NASDAQ:ATRC)
- Goldman Sachs Group Inc. decreased its stake in AtriCure Inc. (NASDAQ:ATRC) by 16.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 76,388 shares of the medical device company’s stock after selling 15,424 shares during the quarter. Goldman Sachs […]
- 04/14/2020
|
AtriCure (NASDAQ:ATRC) Price Target Cut to $41.00 by Analysts at Canaccord Genuity
- AtriCure (NASDAQ:ATRC) had its price target reduced by Canaccord Genuity from $51.00 to $41.00 in a report released on Monday morning, BenzingaRatingsTable reports. Canaccord Genuity currently has a buy rating on the medical device company’s stock. ATRC has been the subject of several other research reports. Piper Sandler lifted their target price on shares of […]
- 04/14/2020
|
Analysts Offer Insights on Healthcare Companies: PolarityTE (PTE) and Atricure (ATRC)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PolarityTE (PTE) and Atricure (ATRC) with bullish
- 04/13/2020
|
Analysts Offer Insights on Healthcare Companies: PolarityTE (NASDAQ: PTE) and Atricure (NASDAQ: ATRC)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PolarityTE (
PTE
–
Research Report
) and Atricure (
ATRC
–
Research Report
) with bullish sentiments.
PolarityTE (PTE)
Northland Securities analyst
Carl By
- 04/13/2020
|
AtriCure Announces CONVERGE IDE Trial Results Accepted for Late-Breaking Clinical Trial Sessions at Annual Heart Rhythm Society (HRS) Meeting
- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that results from the CONVERGE IDE trial have been accepted for presentation in the late-breaking abstract sessions at the Heart Rhythm Society (HRS) Scientific Sessions. The abstract will be presented as a webinar on Heart Rhythm 365, the society’s digital information platform. Specific details on the exact timing of the presentation will follow in a separate announcement.
- 04/13/2020
|
Atricure (ATRC) Gets a Buy Rating from Canaccord Genuity
- In a report released yesterday, Jason Mills from Canaccord Genuity maintained a Buy rating on Atricure (ATRC), with a price target of $41.00. The
- 04/13/2020
|
Atricure (ATRC) Gets a Buy Rating from Canaccord Genuity
- In a report released yesterday, Jason Mills from Canaccord Genuity maintained a Buy rating on Atricure (ATRC – Research Report),
- 04/13/2020
|
Diversified Trust Co Purchases Shares of 7,725 AtriCure Inc. (NASDAQ:ATRC)
- Diversified Trust Co purchased a new stake in AtriCure Inc. (NASDAQ:ATRC) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 7,725 shares of the medical device company’s stock, valued at approximately $259,000. A number of other hedge funds and other institutional investors have […]
- 04/13/2020
|
Canaccord Genuity Maintains Buy on AtriCure, Lowers Price Target to $41
|
Insider Selling: AtriCure Inc. (NASDAQ:ATRC) SVP Sells $350,000.00 in Stock
- AtriCure Inc. (NASDAQ:ATRC) SVP Justin J. Noznesky sold 10,000 shares of the company’s stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $35.00, for a total transaction of $350,000.00. Following the transaction, the senior vice president now owns 61,255 shares of the company’s stock, valued at approximately […]
- 04/12/2020
|
AtriCure Inc. (NASDAQ:ATRC) Shares Bought by Bank of America Corp DE
- Bank of America Corp DE lifted its position in AtriCure Inc. (NASDAQ:ATRC) by 1.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 184,293 shares of the medical device company’s stock after acquiring an additional 3,391 shares during the quarter. Bank […]
- 04/11/2020
|
Mark A. Collar Sells 4,000 Shares of AtriCure Inc. (NASDAQ:ATRC) Stock
- AtriCure Inc. (NASDAQ:ATRC) Director Mark A. Collar sold 4,000 shares of the company’s stock in a transaction dated Tuesday, April 7th. The stock was sold at an average price of $36.07, for a total value of $144,280.00. Following the completion of the transaction, the director now directly owns 73,106 shares of the company’s stock, valued […]
- 04/11/2020
|
AtriCure Inc. (NASDAQ:ATRC) Shares Purchased by Bank of New York Mellon Corp
- Bank of New York Mellon Corp boosted its stake in AtriCure Inc. (NASDAQ:ATRC) by 2.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 322,206 shares of the medical device company’s stock after purchasing an additional 8,681 shares during the quarter. Bank of New York Mellon Corp’s holdings in AtriCure were worth $10,474,000 at […]
- 04/11/2020
|
Q1 2020 Earnings Estimate for AtriCure Inc. Issued By Oppenheimer (NASDAQ:ATRC)
- AtriCure Inc. (NASDAQ:ATRC) – Stock analysts at Oppenheimer issued their Q1 2020 earnings per share estimates for AtriCure in a report released on Monday, April 6th. Oppenheimer analyst S. Kalia forecasts that the medical device company will earn ($0.38) per share for the quarter. Oppenheimer currently has a “Outperform” rating and a $45.00 target price […]
- 04/10/2020
|
Atricure (ATRC) Received its Third Buy in a Row
- After Needham and Piper Sandler gave Atricure (NASDAQ: ATRC) a Buy rating last month, the company received another Buy, this time from Oppenheimer.
- 04/09/2020
|
Atricure (ATRC) Received its Third Buy in a Row
- After Needham and Piper Sandler gave Atricure (NASDAQ:
ATRC
) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst
Suraj Kalia
maintained a
Buy
rating on Atricure today and set a price target of
$45.00
. The
- 04/09/2020
|
AtriCure C-suite taking pay cuts as revenue dips because of coronavirus
- Mike Carrel is CEO of AtriCure.
- 04/09/2020
|
Atricure (ATRC) Gets a Buy Rating from Needham
- In a report released today, Michael Matson from Needham maintained a Buy rating on Atricure (ATRC), with a price target of $49.00. The company's shares
- 04/09/2020
|
Atricure (ATRC) Receives a Buy from BTIG
- BTIG analyst Marie Thibault maintained a Buy rating on Atricure (ATRC) today and set a price target of $45.00. The company's shares closed last Thursday
- 04/09/2020
|
Atricure (ATRC) Receives a Buy from BTIG
- BTIG analyst Marie Thibault maintained a Buy rating on Atricure (ATRC – Research Report) today and set a price target
- 04/09/2020
|
AtriCure announces actions in response to COVID-19 pandemic ATRC
- AtriCure announces actions in response to COVID-19 pandemic ATRC
- 04/09/2020
|
AtriCure reports preliminary Q1 revenue $53.2M, consensus $59.84M ATRC
- AtriCure reports preliminary Q1 revenue $53.2M, consensus $59.84M ATRC
- 04/09/2020
|
AtriCure Announces Preliminary Financial Results for First Quarter 2020 and Provides COVID-19 Pandemic Update
- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the first quarter 2020 and provided updates in response to the COVID-19 pandemic.
- 04/09/2020
|
AtriCure Inc Withdraws Its Previously Announced Financial Guidance For 2020
|
's Top Upgrades, Downgrades For April 7, 2020
- Upgrades
Evercore ISI Group changed the rating for Bank of New York Mellon Corp (NYSE: BK) from Underperform to In-Line. For the fourth quarter, Bank of New York Mellon...
- 04/07/2020
|
AtriCure (NASDAQ:ATRC) Trading 7.5% Higher
- Shares of AtriCure Inc. (NASDAQ:ATRC) traded up 7.5% on Monday . The stock traded as high as $34.45 and last traded at $34.17, 418,428 shares traded hands during mid-day trading. An increase of 5% from the average session volume of 400,122 shares. The stock had previously closed at $31.78. Several research analysts have weighed in […]
- 04/07/2020
|
Oppenheimer Begins Coverage on AtriCure (NASDAQ:ATRC)
- Oppenheimer started coverage on shares of AtriCure (NASDAQ:ATRC) in a research report issued to clients and investors on Monday, TipRanks reports. The firm set a “buy” rating and a $45.00 price target on the medical device company’s stock. Oppenheimer’s price target suggests a potential upside of 31.69% from the company’s current price. A number of […]
- 04/07/2020
|
Oppenheimer Initiates Coverage On AtriCure with Outperform Rating, Announces Price Target to $45
|
Dayton stocks reap massive gains as broad market skyrockets
- Greater Dayton stocks posted impressive gains Monday, along with the broader equity market.
- 04/06/2020
|
Oppenheimer Initiates a Buy Rating on Atricure (ATRC)
- Atricure (ATRC) received a Buy rating and a $45.00 price target from Oppenheimer analyst Suraj Kalia today. The company's shares closed last Monday at
- 04/06/2020
|
Oppenheimer Initiates a Buy Rating on Atricure (ATRC)
- Atricure (ATRC – Research Report) received a Buy rating and a $45.00 price target from Oppenheimer analyst Suraj Kalia today.
- 04/06/2020
|
Head-To-Head Contrast: AtriCure (NASDAQ:ATRC) and Repro-Med Systems (NASDAQ:REPR)
- AtriCure (NASDAQ:ATRC) and Repro-Med Systems (OTCMKTS:REPR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership. Institutional and Insider Ownership 87.3% of AtriCure shares are held by institutional investors. Comparatively, 17.3% of […]
- 04/06/2020
|
Credit Suisse AG Has $879,000 Stock Position in AtriCure Inc. (NASDAQ:ATRC)
- Credit Suisse AG trimmed its position in AtriCure Inc. (NASDAQ:ATRC) by 12.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,015 shares of the medical device company’s stock after selling 3,945 shares during the quarter. Credit Suisse AG […]
- 04/03/2020
|
Dayton stocks dive again after Q1 registers biggest drop since 2008
- Dayton stocks fell Wednesday, along with the broad market.
- 04/01/2020
|
Amalgamated Bank Invests $231,000 in AtriCure Inc. (NASDAQ:ATRC)
- Amalgamated Bank bought a new stake in shares of AtriCure Inc. (NASDAQ:ATRC) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 7,107 shares of the medical device company’s stock, valued at approximately $231,000. Several other hedge funds and other institutional […]
- 04/01/2020
|
AtriCure (NASDAQ:ATRC) Lifted to "Buy" at BidaskClub
- AtriCure (NASDAQ:ATRC) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, BidAskClub reports. A number of other equities research analysts also recently commented on ATRC. BTIG Research upped their price objective on AtriCure from $42.00 to $48.00 and gave the company a “buy” […]
- 04/01/2020
|
Great West Life Assurance Co. Can Acquires Shares of 2,335 AtriCure Inc. (NASDAQ:ATRC)
- Great West Life Assurance Co. Can acquired a new stake in shares of AtriCure Inc. (NASDAQ:ATRC) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 2,335 shares of the medical device company’s stock, valued at approximately $75,000. Other large investors have also recently added […]
- 03/31/2020
|
Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?
- The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
- 03/26/2020
|
Citigroup Inc. Cuts Position in AtriCure Inc. (NASDAQ:ATRC)
- Citigroup Inc. trimmed its position in shares of AtriCure Inc. (NASDAQ:ATRC) by 34.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,812 shares of the medical device company’s stock after selling 4,175 shares during the period. Citigroup Inc.’s holdings in AtriCure were worth $254,000 at […]
- 03/25/2020
|
These Dayton stocks skyrocketed as market posts best day since 1933
- Stock market price display
- 03/24/2020
|
Here's how Dayton stocks fared as Dow falls to lowest level since 2016
- Dayton stocks fared better than the broad market by midday trading, with three of the region's four publicly traded companies gaining value.
- 03/23/2020
|
Peripheral Interventions Market demand to hit USD 11.5 bn by 2026: Global Market Insights, Inc.
- Selbyville, Delaware, March 23, 2020 -- Global Market Insights, Inc. has recently added a new report on peripheral interventions market which estimates the global market.
- 03/23/2020
|
Zacks: Brokerages Expect AtriCure Inc. (NASDAQ:ATRC) Will Announce Quarterly Sales of $59.98 Million
- Wall Street analysts predict that AtriCure Inc. (NASDAQ:ATRC) will post sales of $59.98 million for the current fiscal quarter, Zacks reports. Five analysts have made estimates for AtriCure’s earnings, with the lowest sales estimate coming in at $59.57 million and the highest estimate coming in at $60.90 million. AtriCure reported sales of $53.97 million in […]
- 03/21/2020
|
Atricure Clears Key Benchmark, Hitting 80-Plus RS Rating
|
Atricure Meets 80-Plus Relative Strength Rating Benchmark
|
Electrophysiology Mapping And Ablation Devices Market Size 2020-2023 | In-depth Study, Global Industry Size, Scope, Future Expectations, Market Overview and Forecast Research
- Mar 16, 2020 (The Expresswire) --
Global “Electrophysiology Mapping And Ablation Devices Market” Report 2020 is a comprehensive, professional report provides...
- 03/16/2020
|
AtriCure (NASDAQ:ATRC) Stock Rating Lowered by BidaskClub
- AtriCure (NASDAQ:ATRC) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a report released on Saturday, BidAskClub reports. A number of other brokerages also recently issued reports on ATRC. Needham & Company LLC increased their price objective on shares of AtriCure from $48.00 to $52.00 and gave the stock […]
- 03/14/2020
|
Reviewing AtriCure (NASDAQ:ATRC) & DexCom (NASDAQ:DXCM)
- AtriCure (NASDAQ:ATRC) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings. Valuation and Earnings This table compares AtriCure and DexCom’s revenue, earnings per share (EPS) and valuation. Gross Revenue […]
- 03/14/2020
|
Dayton stocks tumble as Dow falls, ending 11-year bull run
- The Dow Jones Industrial Index fell into bear market territory Wednesday. Here's how Dayton stocks have fared.
- 03/12/2020
|
Charles Schwab Investment Management Inc. Has $7.89 Million Stock Position in AtriCure Inc. (NASDAQ:ATRC)
- Charles Schwab Investment Management Inc. grew its stake in shares of AtriCure Inc. (NASDAQ:ATRC) by 3.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 242,520 shares of the medical device company’s stock after purchasing an additional 8,640 shares during the period. Charles […]
- 03/11/2020
|
Barclays PLC Raises Stake in AtriCure Inc. (NASDAQ:ATRC)
- Barclays PLC lifted its position in shares of AtriCure Inc. (NASDAQ:ATRC) by 100.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 40,012 shares of the medical device company’s stock after buying an additional 20,022 shares during the quarter. Barclays […]
- 03/10/2020
|
PNC Financial Services Group Inc. Has $168,000 Position in AtriCure Inc. (NASDAQ:ATRC)
- PNC Financial Services Group Inc. lessened its holdings in AtriCure Inc. (NASDAQ:ATRC) by 57.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,160 shares of the medical device company’s stock after selling 6,894 shares during the period. PNC Financial Services […]
- 03/08/2020
|
Assetmark Inc. Buys 300 Shares of AtriCure Inc. (NASDAQ:ATRC)
- Assetmark Inc. raised its stake in AtriCure Inc. (NASDAQ:ATRC) by 30.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,275 shares of the medical device company’s stock after purchasing an additional 300 shares during the period. Assetmark Inc.’s holdings in […]
- 03/08/2020
|
The Mechanics Of Fear: Prioritize Cash, Then Health, Cloud, Med-Tech And Social
- Today's note is really a companion piece to yesterday's. Read both. The takeaway is while the market is making its slow climb up, it will retreat multiple times
- 03/04/2020
|
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Increases Stock Position in AtriCure Inc. (NASDAQ:ATRC)
- BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in shares of AtriCure Inc. (NASDAQ:ATRC) by 16.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 651,829 shares of the medical device company’s stock after buying an additional 90,287 shares during […]
- 03/04/2020
|
Head to Head Review: AtriCure (NASDAQ:ATRC) and Sintx Technologies (NASDAQ:SINT)
- AtriCure (NASDAQ:ATRC) and Sintx Technologies (NASDAQ:SINT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability. Profitability This table compares AtriCure and Sintx Technologies’ net margins, return on equity and return on […]
- 03/03/2020
|
AtriCure (NASDAQ:ATRC) Upgraded at ValuEngine
- AtriCure (NASDAQ:ATRC) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday, ValuEngine reports. A number of other analysts also recently commented on the company. BTIG Research upped their price objective on AtriCure from $42.00 to $48.00 and gave the stock a […]
- 03/03/2020
|
Dayton stocks face sharp declines as equity market tumbles
- The stock market tumbled this week, suffering its worst loss since the 2008 financial crisis, and local stocks didn't escape the carnage.
- 02/28/2020
|
AtriCure (ATRC) - Research Analysts' Recent Ratings Changes
- AtriCure (NASDAQ: ATRC) has recently received a number of price target changes and ratings updates: 2/21/2020 – AtriCure was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating. 2/19/2020 – AtriCure was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “AtriCure, […]
- 02/28/2020
|
-$0.37 EPS Expected for AtriCure Inc. (NASDAQ:ATRC) This Quarter
- Equities research analysts expect that AtriCure Inc. (NASDAQ:ATRC) will post ($0.37) earnings per share (EPS) for the current quarter, according to Zacks. Five analysts have issued estimates for AtriCure’s earnings. The lowest EPS estimate is ($0.40) and the highest is ($0.32). AtriCure reported earnings per share of ($0.20) in the same quarter last year, which […]
- 02/27/2020
|
AtriCure Inc. (NASDAQ:ATRC) Shares Acquired by American International Group Inc.
- American International Group Inc. increased its position in AtriCure Inc. (NASDAQ:ATRC) by 1.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 23,795 shares of the medical device company’s stock after buying an additional 364 shares during the quarter. American International Group Inc. owned about […]
- 02/27/2020
|
$59.98 Million in Sales Expected for AtriCure Inc. (NASDAQ:ATRC) This Quarter
- Wall Street analysts forecast that AtriCure Inc. (NASDAQ:ATRC) will announce sales of $59.98 million for the current quarter, according to Zacks. Five analysts have provided estimates for AtriCure’s earnings, with estimates ranging from $59.57 million to $60.90 million. AtriCure posted sales of $53.97 million in the same quarter last year, which would indicate a positive […]
- 02/26/2020
|
